This suggests a potential synergistic effect for the use of immunotherapy in combination with EGFR-TKIs (42), according to the recent evidence of long-lasting antitumor responses of BRAF/MEK inhibitors with immunotherapy in the treatment of BRAF-mutated metastatic melanoma (43). The gene discussed is MAP2K7; the disease is metastatic melanoma.